Nurofen manufacturer Reckitt Benickser has been fined $6 million for misleading customers about its specific pain relief range, in the biggest ever fine for breaching Australian consumer law.
The Federal Court found the manufacturer had misled consumers by claiming its various pain relief drugs targeted different parts of the body when in reality, all of the products contained the same main active ingredient and gave the same result.
The company was initially fined $1.7 million, however this was increased to $6 million after the Australian Competition and Consumer Commission (ACCC) appealed. Reckitt Benickser appealed the higher fine, but was denied.
The manufacturer stood by its products, stating it was “disappointed by the decision”.
“Nurofen did not intend to mislead consumers and we apologise to those of our consumers who were misled,” the company said in a statement.
“We recognise that we could have done more to assist our consumers in navigating the Nurofen specific pain range. That is, to show that each of the products in the range is equally effective for the other pains indicated on the Nurofen specific pain range packaging.”
Nurofen’s targeted pain range has been taken off Australian shelves.